We are international

Call the IMF Hotline. We are here for you. The IMF Office is open from 8:00AM - 5:00PM PST, Monday-Friday.

If you have a question, call the IMF InfoLine at (800) 452-CURE (800-452-2873) in the US and Canada. The InfoLine is open from 9:00 - 4:00 PT Monday - Friday. Elsewhere call (818) 487-7455. You can also contact us via the web.
IMF - Home Page
previous     next      view all

FDA Grants Priority Review for Amgen's sNDA for Expanded Labeling of Kyprolis® in Relapsed Multiple Myeloma
The US Food and Drug Administration (FDA) has agreed for priority review of Amgen’s supplemental new drug application (sNDA) for expanded labeling of Kyprolis (carfilzomib) in relapsed multiple myeloma.

Huge Interest in Toxic Chemicals Triggered by Last Week's Blog: Follow-up Notes
In a follow-up to last week's blog about Agent Orange, IMF Chairman Dr. Brian Durie writes that a new report suggesting a link between home pesticide use and the risk of childhood cancers - especially blood cancers such as leukemia and lymphoma - could have implications for adults. Also, news that New York Times food columnist Mark Bittman is putting down his pen to take action.

Click here to watch the replay of The Military Veterans Perspective on Living with Multiple Myeloma teleconference

Learn more about how veterans with multiple myeloma deal with the disease and how they navigate the VA and other agencies to optimze their resources.  Sandy Kurtin would also discuss the results of the Veteran's Against Myeloma focus group and touch on the current trends in Multiple Myeloma diagnosis & treatment.

More Evidence Links Toxic Chemical Exposure to MGUS and Myeloma
For the first time, direct serum measurements of the known human carcinogen in Agent Orange have been linked to the likelihood of developing MGUS and myeloma. In his blog this week, IMF Chairman Dr. Brian Durie reports on a study, published online Sept. 3 in the journal JAMA Oncology, in which Dr. Ola Landgren and colleagues examined stored serum samples from Vietnam War veterans involved in Operation Ranch Hand, which resulted in significant exposure to a dioxin called TCDD, present in Agent Orange. “This is just one of many studies pointing to the link between toxic chemical exposure and myeloma,” he writes. To read Dr. Durie’s blog, click HERE.

Janssen Submits Marketing Authorisation Application for Daratumumab for European Patients With Heavily Pre-treated Multiple Myeloma
Janssen-Cilag International NV announced on September 9, 2015 it has submitted a new Marketing Authorisation Application to the European Medicines Agency (EMA) for daratumumab, an investigational, human anti-CD38 monoclonal antibody, for the treatment of patients with relapsed and refractory multiple myeloma

U.S. FDA Grants Priority Review to Takeda’s Ixazomib for Patients with Relapsed/Refractory Multiple Myeloma
Takeda Pharmaceutical Company Limited today announced that the U.S. Food and Drug Administration (FDA) has granted Priority Review status to the New Drug Application (NDA) for ixazomib, the first investigational oral proteasome inhibitor for the treatment of patients with relapsed and/or refractory multiple myeloma.

U.S. FDA Grants Priority Review to Janssen for Daratumumab as a Treatment for Multiple Myeloma
Janssen Research & Development, LLC (Janssen) announced today the U.S. Food and Drug Administration (FDA) has accepted for Priority Review the Biologics License Application (BLA) for daratumumab as a treatment for patients with multiple myeloma who are refractory to both a proteasome inhibitor (PI) and an immunomodulatory agent (IMiD), or who have received three or more prior lines of therapy, including a PI and an IMiD. This is referred to as "double refractory" multiple myeloma, which occurs when a patient's disease has become resistant to at least two of the most commonly utilized and active classes of anti-myeloma agents. Daratumumab, an investigational human anti-CD38 monoclonal antibody, received Breakthrough Therapy Designation from the FDA for this patient population in May 2013.

Young Doctors from China Experience IMF's Myeloma Master Class
A group of physicians from leading medical institutions in China came to Los Angeles to learn about myeloma during the International Myeloma Foundation’s recent Myeloma Master Class. In his blog this week, IMF Chairman Dr. Brian Durie, details some of the unique challenges facing these young doctors who, nevertheless, are excited about the future.

IMF Receives Highest 4-Star Charity Rating for 11 Years Running
The IMF has been awarded Charity Navigator’s 4-star, highest rating for 2014! The rating, according to Charity Navigator, indicates that the IMF operates in an ethical and fiscally responsible manner. A 4-star rating is the highest rating a charity can receive from the organization and earning it places the IMF in the “Exceptional” category, meaning the IMF “exceeds industry standards and outperforms most charities in its cause.” Charity Navigator works to promote “a more efficient and responsive philanthropic marketplace, in which givers and the charities they support work in tandem to overcome our nation’s and the world’s most persistent challenges.” We’re proud of our 11-year 4-star rating and honored to serve the myeloma community in finding a cure! Read the detailed rating report, HERE.

FDA Accepts for Priority Review the Biologics License Application for Empliciti (elotuzumab) for the Treatment of MM in Patients Who Have Received One or More Prior Therapies
Bristol-Myers Squibb Company and AbbVie today announced the U.S. Food and Drug Administration (FDA) has accepted for priority review the Biologics License Application (BLA) for Empliciti (elotuzumab), an investigational Signaling Lymphocyte Activation Molecule (SLAMF7)-directed immunostimulatory antibody, for the treatment of multiple myeloma as combination therapy in patients who have received one or more prior therapies.

previous     next      view all